Blog Layout

Global Access Diagnostics (GADx) formed to expand affordable access to advanced rapid diagnostic technologies
Jun 15, 2022
  • GADx combines expertise in the development of rapid diagnostics (Mologic Ltd) with sustainable, volume manufacturing (Global Access Diagnostics) under one organisation
  • First portfolio company of social enterprise Global Access Health (GAH) following acquisition of Mologic 
  • Focused on expanding equitable and affordable access to world-class medical technology in low- and middle-income countries, starting with diagnostics
  • Delivering high value scientific research, product development and manufacturing capabilities on terms that advance the mission


Bedford, UK, June 15, 2022 – Global Access Health (GAH), a social enterprise dedicated to providing affordable medical products for global health, today formally introduced its first portfolio company, Global Access Diagnostics (GADx). GADx has been created to address gaps in the global provision of diagnostics with a focus on expanding affordable access to quality tests. The Company combines expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing and scale-up capability of sister company, Global Access Diagnostics (GAD). 

GADx is a social enterprise where all surplus is re-invested to deliver quality and affordable diagnostics to those in most need. This includes transferring diagnostic technology to low-middle income countries, delivering tests such as COVID-19 to communities in need, and developing tests for neglected diseases such as dengue, bilharzia, and river blindness. It is a unique initiative set up and supported by GAH which was formed in 2021 by a group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation1. Through this transaction, the group acquired Mologic and GAD to harness industry-leading expertise in developing and manufacture of rapid diagnostic technologies. Combining this expertise under the GADx single brand advances the organisation’s philanthropic goals to maximise its contribution to global healthcare.

In addition to its product portfolio, GADx offers world-leading expertise for contract research and development, as well as helping companies to scale-up manufacturing (prototyping to pilot-scale) with capacity to produce over 2 million test per day, and then facilitate local manufacturing and/or onward distribution throughout the world. Through decentralized research, development, and manufacturing in and for the Global South, GADx aims to address gaps in the provision of global diagnostics, in regions that profit-focused business has failed to address.

Nearly half of the world’s population have little or no access to diagnostics; and only 1-in-5 people in low and low-middle income countries have basic diagnostic tests available to them." said Mark Davis, CEO of GADx R&D (formerly Mologic). He added: “GADx’s foundation is based on three pillars: leadership in research and development, manufacturing prowess and Our Core Mission: reinvesting surplus. We are building an innovative social enterprise that puts underserved communities above shareholders and aims to create legacies that bring sustainable change to healthcare and business.” 

Sumin Koo, CEO of GAH, commented: “To be a leader in R&D, we brought in Mologic, a pioneer in rapid diagnostics and already participants in over 150 international research projects and working with globally recognised partners. The team’s expertise and products are at the forefront of human, animal, and agriculture diagnostics.” Sumin Koo, added: “This is paired with the strength of GAD’s novel manufacturing platform; holding the flexibility and expertise to accommodate one-off orders and scale-up for mass production, over 1million tests per day.”

Mark Radford, CEO of GADx Manufacturing (formerly GAD), added: “This is an exciting next step for GADx, harnessing our individual expertise in lateral flow testing to transform rapid diagnostics. We have very well-established contract manufacturing capabilities to provide custom, flexible and scalable solutions, from low- to high-volume. This single brand portrays our group vision for the future of diagnostic testing, we look forward to progressing this to get the best tests to the most people, for the lowest cost and do so sustainably.”

ENDS

Notes to Editors


Media contacts:

Sarah Jeffery, Zyme Communications

+44 (0)7771 730919

sarah.jeffery@zymecommunications.com 


To opt-out from receiving press releases from Zyme Communications please email
info@zymecommunications.com. To view our privacy policy please click here.


About Global Access Diagnostics (GADx) 

Global Access Diagnostics (GADx) is a leading developer and manufacturer of advanced lateral flow and rapid diagnostic technologies. Leveraging our core technology platforms, we work with governments and international organisations, reinvesting our profits to deliver high quality and affordable diagnostics for everyone. 

As a CRMO, GADx offers world-leading expertise for contract research and development as well as helping companies to scale-up manufacturing (prototyping to pilot-scale) with capacity to produce over 2 million test per day. We then facilitate local manufacturing and/or onward distribution throughout the world, with a focus on low- and middle-income countries. 

GADx is actively seeking partners for commercialisation of our product pipeline and those looking to create, scale or manufacture a new point-of-need diagnostic. 

GADx is a Global Access Health (GAH) company and combines expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing and scale-up capability of sister company, Global Access Diagnostics (GAD). We are headquartered in Bedford in the United Kingdom and have a US subsidiary, Mologic Inc. situated in Maine, New Gloucester. 

For more information: www.globalaccessdx.com 

MORE FROM THE NEWSROOM

By Emily Adams 15 Mar, 2024
It is with great pleasure that Mologic Ltd t/a GADx, announces the appointment of our new CEO, starting 1st February 2024, Dr Mark Street-Docherty.
By Emily Adams 31 Jul, 2023
· Test reintroduced to the market following regulatory and performance validation for UKCA marking · Launch supports World Health Organization’s strategic plan for the elimination of life-threatening neglected tropical disease
By Peter Davies 04 May, 2023
London, Thursday 4 th May 2023. Global Access Diagnostics (GADx) announces today that Mr Mark Davis is stepping down as CEO and co-founder after 20 years of unwavering service, having created the organisation Mologic Ltd in June 2003 alongside his father and industry leader, Prof. Paul Davis. Paul was part of the original team that pioneered lateral flow technology and its deployment in the ClearBlue home pregnancy test and together, they guided the company to its position today as a leading innovator and developer of diagnostic products. The move represents a major milestone in the journey of Mologic Ltd to transform from a privately held company to GADx, a social enterprise that reinvests its profits entirely in pursuit of global health programs. Over the past two decades, the organisation embraced creative solutions and blue-sky thinking to partner with hundreds of clients across the globe, to train the next generation of diagnostic innovators in the UK, US, and Senegal, and to develop innovative approaches for unmet diagnostic needs. For several months, the members and Mark Davis have been preparing for this transition, acknowledging the unique skillset and strategy required to grow commercial activities alongside expertise in developing diagnostics for neglected diseases and unmet needs. GADx’ parent company Global Access Health has contracted with the Clinton Health Access Initiative (CHAI) to provide management services to support the organisation through the CEO transition. Dr. Randy Allen, a Director in the Global Markets Team at CHAI will be seconded to the organisation as acting General Manager. Dr. Allen brings a remarkable diversity of experience, commitment, and track record at the intersection of innovative diagnostics and global health programs. He will spearhead the recruitment of a permanent CEO, advance the delivery of the organisation’s key global health programs, and oversee the public launch of GADx’s 2023-2025 strategy. Additional support and expertise will be provided by Alan Staple, a Vice President at CHAI and the Head of the Global Markets Team. Mr Staple brings over 30 years’ management experience and a focus on bringing new products to market, reducing the costs and prices of existing products, and mobilising funding to implement more cost-effective diagnostic solutions and drug regimens. The Members want to thank Mark for his commitment to growing a diagnostics company focussed on meeting unmet needs and ensuring that cutting edge innovation reaches those that need it the most. Mark Davis says: “It has been a privilege to serve as CEO of the company I founded with Paul in 2003. Now is the right time for the organisation to benefit from new leadership that can focus on delivering the current wave of innovations. We have built a fantastic pipeline of products that harness the brilliance of the team and intellectual property at the cutting edge of diagnostic innovation. At the same time, our Contract Partnering Service is flourishing, thanks to the excellent work from our innovation and development teams over the years and the remarkable companies and institutions we are proud to partner with. I welcome this transition wholeheartedly – and hand over a much-cherished organisation to the next generation of leadership that will realise the store of its potential.” About GADx GADx was formed a consortium of social impact investors called Global Access Health, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world. We are headquartered in Bedford in the United Kingdom and have a US subsidiary situated in Maine, New Gloucester.
More Posts
Share by: